ADINA Act
Rep. Morrison Introduces ADINA Act to Require Allergen and Gluten Labels on Medications
The ADINA Act is currently in the early stages of the legislative process and is being reviewed by the House Committee on Energy and Commerce. It is actively moving forward, though no further committee hearings or votes have been scheduled at this time.
Legislative Progress
Key Points
Impact Analysis
Personal Impact
Life & Work
Smaller pharmaceutical and supplement manufacturers would need to update their labeling processes to identify and disclose allergen-derived ingredients. While the two-year implementation window gives companies time to adjust, reformulating labels and verifying ingredient sourcing would add compliance costs, especially for companies with many product lines.
Disabilities
Milestones
Referred to the House Committee on Energy and Commerce.
Sponsor introductory remarks on measure. (CR H2516)
Introduced in House
The bill was officially filed and given a number. It now enters the legislative queue.
Votes
No votes have been recorded for this legislation yet.
Related News
4 articlesMomentum Builds for New ADINA Bill to Label Allergens in Drugs
The ADINA Act (H.R. 3821) was reintroduced in June 2025 by Rep. Kelly Morrison to mandate labeling for the top 9 food allergens and gluten in medications. Advocacy efforts in early 2026 have seen co-sponsors double as families push for federal transparency on prescription and OTC drug labels.
Maple Grove 7th grader on a mission to require medications list allergens
Profiles Adina Togal, whose hospitalization from an antibiotic with undisclosed allergens inspired the ADINA Act. The bill seeks to close a loophole where pharmaceutical drugs, unlike food products, are not required to list potential allergens like gluten or lactose in their inactive ingredients.
ADINA Act would require allergen labeling on OTC, prescription medication
The Allergen Disclosure in Non-Food Articles (ADINA) Act would amend the Food, Drug, and Cosmetic Act to require drug labels to indicate ingredients derived from major food allergens or glutens. Research shows 93% of medicines contain potential allergens, often in undisclosed inactive ingredients.
Source Information
Document Type
Congressional Bill
Official Title
ADINA Act
Data Sources
Sponsor
Cosponsors
(17)Analysis generated by AI. Always verify with official sources.